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Objectives: Cytomegalovirus (CMV) infection is responsible for significant morbidity and mortality
among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) in orthotopic liver
transplant (OLT) recipients is not approved by the Food and Drug Administration and its use is contro-
versial. This study aimed to evaluate the effectiveness of VGCV in CMV prophylaxis in OLT recipients.
Methods: We carried out a retrospective, single-centre study including all OLT procedures performed
during 2005–2008. Patients with early death (at 30 days), without CMV serology or prophylaxis, or with
follow-up of <1 year were excluded.
Results: The overall incidence of CMV disease was 6% (n = 9). The ganciclovir (GCV) and VGCV groups
had similar incidences of CMV disease (4.6% vs. 7.0%; P = 0.4) and similar distributions of disease
presentation (CMV syndrome vs. tissue-invasive CMV; P = 0.4). Incidences of CMV infection, as well as
disease presentation, were similar between the high-risk (CMV D+/R-) and non-high-risk groups (P =
0.16). Although acute cellular rejection occurred more frequently in patients who developed CMV disease
(P = 0.005), overall survival in these patients did not differ from that in patients who did not develop CMV
infection (P = 0.5).
Conclusions: Valganciclovir is an effective antiviral for the prevention of CMV disease in liver transplant
recipients. Our data support its use in high-risk OLT patients.
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Introduction
Cytomegalovirus (CMV) infection is responsible for significant
morbidity and mortality among solid organ transplant
recipients.1–5 The onset of symptomatic CMV infection generally
occurs during the first 3 months post-transplant in patients who
do not receive antiviral prophylaxis. Strategies for CMV disease
prevention include pre-emptive therapy or antiviral prophylaxis,
with the latter being the more commonly utilized, especially in the
high-risk CMV donor-positive/recipient-negative (D+/R-) set-
ting.5,6 Antiviral regimens that have been shown to be effective in
preventing CMV infection in orthotopic liver transplant (OLT)
recipients include i.v. and oral ganciclovir (GCV).7–9
Although it has proved to be successful in preventing the devel-
opment of CMV disease, the i.v. administration of GCV requires
longterm access that carries a potential risk in immunocompro-
mised recipients, whereas oral GCV requires frequent dosing with
a significant pill burden because of its poor bioavailability.9,10 To
overcome the limitation of oral and i.v. GCV, valganciclovir
(VGCV), a valyl ester prodrug of GCV with 10-fold greater
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bioavailability than oral GCV, was developed as an attractive alter-
native.11 A prospective, multicentre, randomized trial comparing
the efficacy and safety of VGCV with those of oral GCV found
VGCV to be well tolerated and effective for CMV disease preven-
tion in high-risk heart, kidney and kidney + pancreas transplant
recipients.12 By contrast, the incidence of CMV disease in OLT
recipients at 6 months was higher in the VGCV than the GCV
group, with tissue-invasive CMV disease representing the major-
ity of CMV cases.12,13 Accordingly,VGCV did not receive Food and
Drug Administration (FDA) approval for prophylaxis in OLT
recipients. A recent survey by Levitsky et al.6 reported that the
majority of liver transplant centres in the USA and Canada
had not changed their practice and that VGCV was the most
commonly used agent for CMV prophylaxis, even in high-risk
liver transplant recipients.
The intent of this study is to retrospectively examine the non-
inferiority of our current VGCV regimen in the prevention of
CMV disease compared with that of our previous regimen using
oral GCV.
Materials and methods
Study design
This study was approved by the institutional review board of the
University of Maryland Medical Center, Baltimore, MD, USA. All
OLT recipients whose procedures were performed during the
period from January 2005 to December 2008 were retrospectively
evaluated. Data sources included electronic hospital and trans-
plant records, as well as paper records. Patients who had an early
death (at 30 days of transplant), incomplete records (CMV
status or prophylaxis type), were alive with follow-up of <1 year,
or had received any prophylaxis other than GCV or VGCV were
excluded.
For data analysis, recipients were divided into two groups based
on the type of CMV prophylaxis agent received (either GCV or
VGCV). Recipients were also divided according to their risk for
developing CMV disease (high-risk group, CMV D+/R-; non-
high-risk group, all other serologic combinations). Recipients
who required a retransplantation during the study period were
grouped based on the type of prophylaxis used in the later OLT.
Cytomegalovirus prophylaxis protocol
In high-risk recipients, CMV prophylaxis consisted of i.v. GCV
5 mg/kg/day for 14 days (or until discharge), followed by either
oral GCV 1 g three times/day (prior to June 2007) or VGCV
900 mg/day (from June 2007) for 90 days after transplantation.
Non-high-risk patients were given either oral GCV or VGCV
therapy immediately following transplantation, which was con-
tinued for 90 days. All antiviral prophylactic regimens were dose-
adjusted for renal function.
Outcome measures
The primary outcome measure was the development of CMV
disease. The overall incidence of CMV infection was compared
between patients receiving prophylaxis with VGCV and those
receiving oral GCV. Subgroup analysis of high-risk recipients
(CMV D+/R-) was also conducted. Cytomegalovirus disease was
defined as CMV syndrome or tissue-invasive CMV infection.
Patients were considered to have CMV syndrome when they pre-
sented with a clinical suspicion of CMV disease (fever,malaise and
leucopoenia) and CMV viraemia was detected (CMV DNA using
polymerase chain reaction). Tissue-invasive CMV disease was
defined by organ dysfunction not attributed to other pathology
with evidence of CMV in a biopsy specimen of the affected organ.
Routine surveillance for CMV viraemia was not performed during
or after the completion of the prophylaxis therapy. Similarly, tissue
biopsies were performed only when clinically indicated. Other
outcome measures included rejection episodes, patient and graft
survival.
Immunosuppression regimen
High-dose i.v. methylprednisolone was used uniformly in all
transplant recipients during the first 3 days following transplan-
tation. Basiliximab (Simulect®; Novartis International AG, Basel,
Switzerland) induction was used for simultaneous liver + kidney
transplants, as well as in OLT recipients with poor preoperative
renal function. Maintenance immunosuppression consisted of a
calcineurin inhibitor (tacrolimus or cyclosporine), mycopheno-
late mofetil (MMF) and oral prednisone. The target tacrolimus
12-h trough level was 6–8 ng/ml for the first 3 months, followed
thereafter by a target trough level of 4–6 ng/ml (tandem mass
spectrometry). Mycophenolate mofetil 500 mg twice/day was
initiated immediately post-transplant, with dose adjustment for
gastrointestinal intolerance or leucopoenia. Oral prednisone was
tapered off over 21 days.
Statistical analysis
Data analyses utilized chi-squared and t-tests for categorical vari-
ables and analysis of variance (anova) for continuous variables.
Kaplan–Meier survival curves were used to estimate patient and
graft survival rates. Log-rank tests were used to evaluate differ-
ences between the GCV andVGCV groups. Statistical calculations
were performed using spss for Windows, Version 18 (SPSS, Inc.,
Chicago, IL, USA). A P-value of 0.05 was considered significant.
Results
Between January 2005 and December 2008, 179 adult liver trans-
plants were performed. Nineteen cases were excluded (eight
patients died at 30 days, five received acyclovir for prophylaxis,
three lacked prophylaxis records, two were alive with <1 year of
follow-up, and one lacked pre-OLT CMV recipient serology).
During the study period, nine patients required a second OLT and
thus only data for the second transplant were included. Accord-
ingly, the study cohort included 151 OLT cases. Sixty-five patients
received GCV and 86 patients received VGCV. The baseline and
demographic characteristics of the recipients were comparable
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between the GCV andVGCV groups (Table 1). Donor age, gender,
ethnicity, type (brain-dead, donation after cardiac death) and pre-
servative solution used were similar between the two groups (P >
0.05). Operative data including cold ischaemia time, second OLT,
simultaneous organ transplant, and intraoperative blood, fresh
frozen plasma and platelet transfusion requirements were similar
in the two groups (P > 0.05).A total of 42 high-risk recipients were
similarly distributed across the GCV (n = 17) and VGCV (n = 25)
groups (P = 0.4) (Table 2). The use of basiliximab (Simulect®)
induction was similar between the GCV and VGCV groups (35%
vs. 24%, respectively; P = 0.12). At discharge, 6 and 12 months
post-transplant, MMF was utilized by 36 (55%), 38 (60%) and 32
(50%) patients, respectively, in the GCV group and by 74 (86%),
58 (69%) and 53 (63%) patients, respectively, in the VGCV group
(P > 0.05). Themean tacrolimus 12-h trough levels in each quarter
during the first year were similar between the GCV and VGCV
groups (P > 0.05). The majority of the patients in both the GCV
and VGCV groups completed 90 days of prophylaxis (92% and
88%, respectively; P = 0.4).
Overall, 6.0% (n = 9) of the patients developed CMV disease;
five patients presented with CMV syndrome and four patients
developed tissue-invasive CMV infection, including CMV colitis
(n = 3) and CMV hepatitis (n = 1). The incidence of CMV disease
in the GCV andVGCV groups was similar (4.6% vs. 7.0%, respec-
tively; P = 0.4). In addition, types of infection (CMV syndrome or
tissue-invasive disease) were similarly distributed across the GCV
and VGCV groups (P = 0.4) (Table 3). A total of 3.1% (n = 2) of
patients in the GCV group and 2.3% (n = 2) of patients in the
VGCV group had evidence of tissue-invasive disease (P = 0.4). Of
the nine CMV cases, seven (78%) were delayed onset (i.e. CMV
developed after the completion of antiviral prophylaxis) and two
(22%) were breakthrough cases. Both of the breakthrough cases
occurred in the VGCV group. However, because of the small
number of breakthrough cases, meaningful analysis is difficult.
The incidence of CMV disease and the type of infection were
similar between the high-risk (CMV D+/R-) and non-high-risk
groups (P = 0.16) (Table 4), with a single breakthrough infection
Table 1 Recipient characteristics
Total
(n = 151)
GCV
(n = 65)
VGCV
(n = 86)
P value
Mean age (range), years 54 (19–73) 55 (32–73) 53 (19–72) 0.2
Male gender, n (%) 110 (73%) 51 (79%) 59 (69%) 0.1
African-American/White, %/% 26/74 26/74 26/74 0.5
Location prior to TXP, home/hospital/ICU, % 71/15/14 73/14/13 70/15/15 0.8
BMI > 30, n (%) 48 (32%) 24 (37%) 24 (28%) 0.2
Status 1Aa, n (%) 13 (8.6%) 3 (4.6%) 10 (11.6%) 0.1
Calculated mean MELD score (range) 22 (6–62) 21 (6–62) 23 (6–44) 0.3
HCV+ serology, n (%) 85 (56%) 40 (62%) 45 (52%) 0.2
Pre-OLT renal failureb, n (%) 38 (25%) 20 (31%) 18 (21%) 0.1
Primary diagnosis
• Etoh, n (%) 15 (9.9%) 7 (10.7%) 8 (9.3%) 0.4
• HCV, n (%) 69 (45.7%) 33 (50.8%) 36 (41.9%) 0.4
• HBV, n (%) 12 (7.9%) 6 (9.2%) 6 (7.0%) 0.4
• NASH/cryptogenic, n (%) 20 (13.3%) 9 (13.8%) 11 (12.8%) 0.4
• HCC, n (%) 11 (7.3%) 4 (6.2%) 7 (8.1%) 0.4
• Other, n (%) 24 (15.8%) 6 (9.2%) 18 (20.9%) 0.4
There were no significant differences in patient demographics, renal function and underlying disease between patient groups
aStatus 1A: fulminant liver failure with life expectancy of <1 week without a liver transplant (including fulminant hepatic failure, primary non-function
or hepatic artery thrombosis within 1 week of implantation and acute decompensated Wilson's disease)
bRenal failure (including patients requiring dialysis or with a glomerular filtration rate of 29 at time of transplant calculated with the modification of
diet in renal disease [MDRD] equation)
GCV, ganciclovir; VGCV, valganciclovir; TXP, transplant; ICU, intensive care unit; BMI, body mass index at transplant; MELD, Model for End-Stage
Liver Disease; HCV, hepatitis C virus; OLT, orthotopic liver transplantation; Etoh, alcoholic cirrhosis; HBV, hepatitis B virus; NASH, non-alcoholic
steatohepatitis; HCC, hepatocellular carcinoma
Table 2 Distribution of the study cohort
GCV
n (%)
VGCV
n (%)
P-value
Total number (n = 151) 65 (43%) 86 (57%) 0.4
• Low-risk group (n = 109) (72%) 48 (74%) 61 (71%) 0.4
• High-risk group (n = 42) (28%) 17 (40%) 25 (60%) 0.4
All recipients and the high-risk group were evenly distributed across the
GCV and VGCV groups
GCV, ganciclovir; VGCV, valganciclovir
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in each group. In subgroup analysis of the high-risk recipients, the
overall incidence of CMV disease was 9.5% (n = 4), with similar
distributions in the GCV (n = 2, 11.7%) and VGCV (n = 2, 8.0%)
groups. The overall incidence of tissue-invasive CMV disease
among high-risk OLT recipients was 7.1% (n = 3), with one case
occurring in the GCV group (5.8%) and two in the VGCV group
(8.0%).
Rejection episodes occurred in 66.6% (n = 6) of the patients
who developed CMV infection compared with 20.4% (n = 29) of
patients without CMV infection (P = 0.005). In four of the six
patients who experienced both allograft rejection and CMV infec-
tion, the rejection episodes, which were treated with pulse meth-
ylprednisolone, occurred first and were followed by the CMV
infection. The mean duration between the treatment of rejection
episodes and the development of CMV disease was 240 days
(range: 37–445 days). Of the nine patients with CMV disease,
three were treated with i.v. GCV, four were started initially on i.v.
GCV and then transitioned to VGCV, and one patient was treated
only with VGCV. One patient was started on i.v. GCV in combi-
nation with CMV immunoglobulin and foscarnet as a result of
persistent CMV viraemia and tissue-invasive CMV hepatitis, and
was subsequently transitioned to oral VGCV. Rates of patient and
graft survival were similar in recipients who did and did not
experience CMV infection (Table 5, Fig. 1). Similarly, there was no
difference in patient or graft survival between patients who
received GCV or VGCV for antiviral prophylaxis (Table 5, Fig. 2).
Discussion
Cytomegalovirus infection causes significant morbidity and mor-
tality among solid organ transplant recipients.1–5 Because of its
10-fold greater bioavailability, higher GCV exposure after oral
administration, less frequent medication administration and
lower pill burden, which might improve patient compliance,
VGCV appeared to be an attractive alternative to oral GCV.11,14
Although the efficacy and safety of VGCV in the prevention of
CMV disease has been established in heart, kidney and kidney +
pancreas transplant patients, controversies regarding the use of
VGCV in liver transplant recipients remain.
In a prospective, randomized, double-blind, double-dummy,
multicentre clinical study, Paya et al. evaluated the efficacy and
safety of VGCV vs. oral GCV for the prevention of CMV disease in
high-risk solid organ transplants.12 At 6 months post-transplant,
the overall incidence of CMV disease was found to be 12.1% in the
Table 3 Incidence and distribution of cytomegalovirus disease
Total cohort
(n = 151)
GCV group
(n = 65)
VGCV group
(n = 86)
P-valuea
Any CMV disease, n (%) 9 (6.0%) 3 (4.6%) 6 (6.9%) 0.4
• CMV syndrome, n (%) 5 (3.3%) 1 (1.5%) 4 (4.6%) 0.4
• Tissue-invasion CMV, n (%) 4 (2.6%) 2 (3.1%) 2 (2.3%) 0.4
aThere was no statistically significant difference in distribution or type of CMV disease in patients receiving GCV or VGCV for prophylaxis
GCV, ganciclovir; VGCV, valganciclovir; CMV. cytomegalovirus
Table 4 Cytomegalovirus (CMV) disease in non-high-risk and high-risk groups
Total cohort
(n = 151)
Non-high-risk
(n = 109)
High-risk
(n = 42)
P-valuea
Any CMV disease, n (%) 9 (6.0%) 5 (4.6%) 4 (9.5%) 0.16
• CMV syndrome, n (%) 5 (3.3%) 4 (3.6%) 1 (2.3%) 0.16
• Tissue-invasion CMV, n (%) 4 (2.6%) 1 (0.9%) 3 (7.1%) 0.16
aThere was no statistically significant difference in distribution or type of CMV disease in non-high-risk vs. high-risk liver transplant recipients
Table 5 Patient and graft survival rates
1-year patient survival P-value 1-year graft survival P-value
Prophylaxis type
• GCV 84.6% 0.8 84.6% 0.9
• VGCV 84.2% 84.2%
CMV infection
• Yes 77.8% 0.5 77.8% 0.6
• No 85.1% 85.1%
Patient and graft survival were not affected by type of prophylaxis or occurrence of CMV disease
CMV, cytomegalovirus; GCV, ganciclovir; VGCV, valganciclovir
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VGCV group and 15.2% in the GCV group and the difference in
proportions between the groups was 0.034 (95% confidence inter-
val [CI] -0.042 to 0.11). However, a statistically significant inter-
action between treatment and organ type was observed (P =
0.017). There were significantly lower numbers of cases of CMV
disease in the VGCV group among recipients of heart, kidney and
kidney + pancreas transplants. By contrast, the incidence of CMV
disease among OLT recipients was higher in the VGCV group
compared with the GCV group (19% vs. 12%, respectively).
Although this was not statistically significant, the majority of cases
in the VGCV group involved tissue-invasive disease (14% vs. 3%,
respectively).12,13 Based on the results of this study, VGCV was
approved for the prevention of CMV disease in kidney, heart and
kidney + pancreas transplant patients, but not in liver transplant
recipients. These findings prompted other transplant centres to
examine the effectiveness of VGCV in the prevention of CMV
disease in their patient populations.
In a prospective, non-comparative, observation study, Jain et al.
evaluated the effectiveness of VGCV in the prevention of CMV
infection in liver transplant patients.15 Symptomatic CMV disease
occurred in 29 of the 203 study patients (14.3%) and eight
(25.9%) of the patients developed the infection while still on
VGCV prophylaxis. Based on these findings, the authors con-
cluded that VGCV failed to provide adequate protection against
CMV disease in OLT recipients.
Recently, Shiley et al. reported an increased incidence of CMV
syndrome and tissue-invasive disease in high-risk OLT recipients
after completion of VGCV prophylaxis compared with recipients
who received GCV.10 Cytomegalovirus disease developed in six
patients (22.2%) in the VGCV group compared with two patients
(5.1%) in the GCV group (P = 0.056; relative risk, 4.33; 95% CI
0.94–19.87), with a mean onset of 190 days post-transplant. Based
on the four-fold higher incidence of CMV disease in the VGCV
group, the authors recommended avoiding the use of VGCV for
prophylaxis in high-risk OLT recipients.10
In our current study, the overall incidence of CMV disease is
less than those reported in previous studies. In addition, the
overall occurrence and distribution of CMV disease (syndrome vs.
tissue-invasive) were similar in patients receiving GCV or VGCV
prophylaxis. In the high-risk group, the overall incidence of CMV
disease and the type of infection were also similar between the
GCV and VGCV groups.
Our findings contrast with the results of the three studies men-
tioned previously. In the multicentre study by Paya et al.,12 various
immunosuppressive regimens were used based on the standard of
practice of each individual centre participating in the study, and
induction medications, target calcineurin inhibitor goals, fre-
quency of MMF used and additional medications used were not
clearly reported. In the study by Shiley et al.,10 the target tacroli-
mus trough was unclear, whereas in the study by Jain et al.,15 the
target tacrolimus trough was higher, especially in the first 3
months post-OLT (8–12 ng/ml), compared with our practice.
Hence, the higher incidence of CMV disease in the previous
reports may be explained, in part, by differences in the immuno-
suppressive burden. In our study, there was a significant correla-
tion between the occurrence of CMV infection and rejection
episodes. In the majority of patients who experienced both events,
CMV infection occurred after the treatment of rejection with
Figure 1 Patient survival and cytomegalovirus (CMV) disease.
CMV+, patients with CMV disease; CMV-, patients without CMV
disease. —— number at risk
Figure 2 Patient survival and cytomegalovirus prophylaxis. VGCV,
valganciclovir; GCV, ganciclovir. —— number at risk
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high-dose methylprednisolone, which may have precipitated the
development of the infection.
It has been hypothesized that hepatic esterases, which are
required to convertVGCVtoGCV,maybe insufficient immediately
after OLT while the new liver recovers its function.15 In a prospec-
tive, randomized, open-label, crossover study, Pescovitz and col-
leagues examined the pharmacokinetic profiles of GCV andVGCV
in 24 stable liver transplant recipients.11 They found that in the
non-steady state, 24-h area under the curve (AUC24) values of
systemic GCV exposure were similar following administration of
VGCV 450 mg/day compared with oral GCV 1 g three times/day
(21.1 mg h/ml vs. 20.7 mg h/ml, respectively), and following
administration of VGCV 900 mg compared with i.v. GCV 5 mg/kg
(41.7 mg h/ml vs. 48.2 mg h/ml, respectively). The same study
found estimated absolute bioavailability to be 6.3% for oral GCV,
60.0% for VGCV 450 mg, and 59.0% for VGCV 900 mg. In addi-
tion, Wiltshire et al. reported a pharmacokinetic analysis with
greater systemic GCV exposure in patients receiving oral VGCV
(900 mg/day) compared with patients on oral GCV (1 g three
times/day), which correlates with increased suppression of CMV
viral replication.16 Systemic GCV exposure after VGCV adminis-
tration was also shown to be consistent across various allograft
types.12 Although no pharmacokinetic data are available forVGCV
in the immediate post-OLT period, VGCV is effective for CMV
prophylaxis during this time period, as evidenced by the delayed
onset of CMVdisease inour study aswell as in the literature.10,12,17–19
The effectiveness of VGCV in CMV prophylaxis in OLT recipi-
ents demonstrated in our study is in agreement with other reports
in the literature. In a retrospective study, Park et al. reported a
similar overall incidence of CMV disease within 1 year post-OLT
in patients receiving GCV (1 g three times/day) and low-dose
VGCV (450 mg/day) (4% [n = 2] and 3% [n = 2], respectively)
with three of the four CMV cases occurring in the high-risk
group.18 In another study that included 67 CMV high-risk OLT
recipients, Arthurs et al. found no differences in the incidence of
delayed-onset CMV disease between the group of patients who
received oral GCV at 1 g three times/day (22%) and those who
received VGCV at 900 mg/day (28%).17 This study identified
female gender and younger age at time of transplant as risk factors
for the development of delayed-onset CMV disease. Neither of
these factors was associated with higher risk for CMV disease in
our study. In a more recent study that included a cohort of 64
CMV high-risk OLT recipients, Brady et al. reported a similar
incidence of CMV disease within 1 year post-transplant in recipi-
ents who received VGCV (n = 3, 7%) or GCV (n = 1, 5%) for
prophylaxis (P = 1.0).19 By contrast with our CMV prophylaxis
protocol, Brady et al. reported utilizing a lower VGCV dose
(450 mg/day) for a prolonged duration (6 months).
Given these favourable results, VGCV continues to represent
the agent most commonly used for CMV prophylaxis by the
majority of liver transplant centres in the USA and Canada,
including in high-risk OLT recipients and despite the absence of
FDA approval.6
Because of the favourable pharmacokinetic profile of VGCV
and the ease with which it can be administered, its safety and
efficacy as a therapeutic option for the treatment of CMV disease
after solid organ transplantation were examined. In a large cohort
of solid organ transplant recipients (n = 3467), including OLT
recipients, VGCV was used as a therapeutic modality for pre-
emptive therapy, and for the treatment of viral syndrome or focal
disease, with rates of success similar to those of classic therapy
with i.v. GCV.20 In our cohort, as well as in other reports, VGCV
was used successfully as a single agent or following i.v. GCV to
treat patients with CMV disease.17,18
In our study, the majority of CMV cases had delayed-onset
disease presentation, which is similar to the onset observed in
other studies.10,12,15 This remains a serious clinical concern. To
address this issue, some authors have suggested a strategy of pro-
longing the duration of antiviral prophylaxis regimens,21 whereas
others have suggested that the increase in the severity of delayed-
onset CMV disease, specifically in terms of tissue-invasive infec-
tion, may be caused by prolonged exposure to GCV or VGCV
that delays the recovery of CMV-specific T cell responses, a
hypothesis that favours a pre-emptive strategy rather than
routine prophylaxis.22 Interestingly, Kijpittayarit et al. reported
the development of delayed-onset CMV disease with fever and
viraemia in a lung transplant recipient 6 weeks after the discon-
tinuation of antiviral prophylaxis with oral GCV that had been
administered for 5.5 years.23
In our study, rates of graft and patient survival among recipi-
ents who received GCV were similar to those in patients onVGCV
and, furthermore, graft and patient survival were not adversely
affected by the occurrence of CMV disease. This is similar to
findings in other published reports12,17 and implies diminished
adverse effects of CMV disease on liver allograft outcomes and
patient survival in the era of antiviral prophylaxis.
We acknowledge the limitations of our study, including its ret-
rospective, non-randomized design. As a result, we may have
failed to account for a number of confounding variables in the
analysis. In addition, because this report recounts a single-centre
experience and has a small total sample size, the universality of
our results may be limited. Furthermore, the different time
periods for which GCV and VGCV were administered may have
indirectly influenced other aspects of care whichmight have influ-
enced the occurrence of CMV.
Conclusions
The results of our study suggest that VGCV is safe, effective and
non-inferior to GCVwhen used in the prevention of CMV disease
in OLT recipients, including the high-risk group. Valganciclovir
has several additional advantages, including its higher oral bio-
availability, higher GCV exposure after oral administration, and
lower pill burden compared with oral GCV. In the wake of the
improvements in the antiviral prophylaxis regimen that result
from the use of either GCV or VGCV, the onset of CMV disease
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has shifted from the early post-transplant period to the period
after the completion of the antiviral prophylaxis regimen. A large
prospective trial of VGCV with stratified randomization for dura-
tion of therapy based on CMV D/R risk compared with a
pre-emptive strategy may help to define the optimal method of
prophylaxis, as well as the duration of treatment for each group
and may further decrease the occurrence of late CMV disease.
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